STAT3 and non-small cell lung carcinoma: STAT3 is persistently activated in over 50% of NSCLC patients [31,32], and its increased expression is associated with poor tumor differentiation, advanced clinical stage, lymph node metastasis, and drug resistance [33,34,35].